Effect of Antiplatelet Drugs on D-Dimer Levels: A Systematic Review and Meta-analysis.

Abstract

AIMS:

D-dimer is a product of fibrinolysis. In clinical practice, D-dimer levels are commonly used to rule out venous thromboembolism. Antiplatelet drugs may influence D-dimer levels, potentially affecting the accuracy of this diagnostic tool. To evaluate the effect of antiplatelet drugs on D-dimer levels, we performed a systematic review and meta-analysis of all published articles on this topic (PROSPERO registration number CRD42017058932).

METHODS AND RESULTS:

We electronically searched EMBASE, MEDLINE Epub, Cochrane, Web of Science, and Google Scholar (100 top relevance) (last search on October 5, 2017). We included randomized controlled trials, cohort studies, and cross-sectional studies conducted in humans, with a drug exposure time of at least 7 days. Two reviewers independently selected eligible articles and extracted the data. Five controlled trials, 7 cohort studies, and 5 cross-sectional studies were finally included. Meta-analysis involving all 1117 participants showed no change in dimer levels (standardized mean difference: -0.015, 95% confidence interval, 0.182-0.151, P = 0.855).

CONCLUSIONS:

In conclusion, antiplatelet drugs do not seem to influence D-dimer levels.

• Authors: Francesca Morelli, Suzanne Schol-Gelok, Lidia R Arends, Eric Boersma, Marieke J H A Kruip, Jorie Versmissen, Teun van Gelder
• Journal: Journal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 73 Issue 6 Pg. 343-351 (06 2019) ISSN: 1533-4023 [Electronic] United States
• PMID: 31162242 (Publication Type: Journal Article, Meta-Analysis, Systematic Review)

Chemical References

• Biomarkers
• Fibrin Fibrinogen Degradation Products
• Platelet Aggregation Inhibitors
• fibrin fragment D

Topics

• Adult
• Aged
• Aged, 80 and over
• Biomarkers (blood)
• Blood Chemical Analysis
• Female
• Fibrin Fibrinogen Degradation Products (metabolism)
• Fibrinolysis (drug effects)
• Humans
• Male
• Middle Aged
• Platelet Aggregation Inhibitors (therapeutic use)
• Predictive Value of Tests
• Reproducibility of Results
• Venous Thromboembolism (blood, diagnosis)
• Young Adult